Vivus Inc (VVUS) Files Form 4 Insider Selling : Santosh T Varghese Sells 366 Shares

Vivus Inc (VVUS): Santosh T Varghese , VP, Medical & Reg Affairs of Vivus Inc sold 366 shares on Jul 1, 2016. The Insider selling transaction was reported by the company on Jul 6, 2016 to the Securities and Exchange Commission. The shares were sold at $1.21 per share for a total value of $442.86 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 20, 2016, John L Slebir (SVP, Business Development & GC) sold 9,933 shares at $2.20 per share price.On Apr 20, 2016, Guy P Marsh (VP, US Operations & GM) sold 633 shares at $3.04 per share price.Also, On Apr 20, 2016, Wesley Day (VP, Clinical Development) sold 2,549 shares at $3.04 per share price.On Apr 11, 2016, Santosh T Varghese (Chief Medical Officer) sold 329 shares at $1.65 per share price.

Shares of VIVUS (VVUS) ended Tuesday, Jul 6, 2016 session in red amid volatile trading. The shares closed down -0.05 points or -4.10% at $1.17 with 2,29,557 shares getting traded. Post opening the session at $1.21, the shares hit an intraday low of $1.1403 and an intraday high of $1.24 and the price vacillated in this range throughout the day. The company has a market cap of $122 M and the number of outstanding shares has been calculated to be 10,40,89,388 shares. The 52-week high of VIVUS is $2.38 and the 52-week low is $0.915.

VIVUS Money Flow Index Chart

Company has been under the radar of several Street Analysts.VIVUS is Downgraded by WallachBeth to Hold. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on May 4, 2016.

VIVUS Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products. It provides two therapies approved by the Food and Drug Association (FDA) which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company is also developing and has completed the Phase II studies of Qsymia for the indication of OSA and diabetes. Qsymia is available in over 42000 certified retail pharmacies across the country. STENDRA is also approved by the European Commission (EC) under the name SPEDRA for the treatment of ED in the Europe. As of September 18 2014 the FDA approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Leave a Reply

VIVUS - Is it time to Sell?

Top Brokerage Firms are advising their investors on VIVUS. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.